Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Recruiting
Phase 1
Phase 2
Interventional Study
Relapse/Refractory B-cell Acute Lymphoblastic Leukemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 2 – 18
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 5 (estimated)
- Sponsor
- Kara Yakhteh Tajhiz Azma Company · Research network
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to evaluate the safety and efficacy of CD19 CAR-T cells in pediatric patients of all genders, aged 2 to 18 years, with relapsing or refractory B cell acute lymphoblastic leukemia (r/r B-ALL). The main questions it aims to answer are as following:
1. What is the percentage of patients with overall remission rate (ORR) of complete response (CR) or complete remissi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Ages 2 to 18 years with relapsed or refractory CD19+ B-ALL
* Presence of disease in the bone marrow
* Able to tolerate the apheresis process
* Life expectancy \> 12 weeks
* Lansky or Karnofsky score \> 50%
* At least 7 days passed since the last chemotherapy and the last…
Contacts